Su1049 Faldaprevir Plus Pegylated Interferon Alfa-2A and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C Genotype-1 Infection: A Pooled Analysis of Two Randomized, Double-Blind Placebo-Controlled Phase III Trials (Startverso1&2)

Abstract

A S L D A b st ra ct s Retrospective cohort study using data from Kaiser Permanente Southern California. Study participants were ≥18 years old with a diagnosis and/or a positive lab result for HCV RNA and ≥6 months continuous membership plus drug benefit prior to HCV treatment. Baseline demographics and comorbid illnesses representing absolute or relative contraindications to treatment with peginterferon, ribavirin, boceprevir, or telaprevir were determined. Multivariate logistic regression was used to determine predictors of treatment. Results: From Jan 2002 through Dec 2012, 51,984 HCV patients were identified and 7,945 (15.3%) of this population received treatment. After applying exclusion criteria, 32,283 patients were identified, of which 26,750 received no treatment and 5,533 received treatment. Factors significantly associated with receipt of treatment were age 45-65, male gender, cirrhosis, HIV, non-alcoholic fatty liver disease (NAFLD), depression, and prior liver transplant. Factors significantly associatedwith receiving no treatment are seen in Table 1. Conclusion: Treatment of HCV with peginterferon-based regimens is significantly limited by numerous comorbid conditions. Future treatment may be better tolerated and with fewer contraindications, thus increasing treatment effectiveness and thereby reducing future morbidity and mortality of liver disease.